Ping An Biomedical Co., Ltd. (PASW) Cash Flow Statement
Where PASW’s cash came from and went, FY2025
September 30, 2025 · Chinese yuan- Cash from operations
- −CN¥6.4M −143.9% vs FY2024
- Capital expenditures
- CN¥0 0.0% of revenue
- Free cash flow
- −CN¥6.4M −18.8% margin
- Returned to shareholders
- —
- Change in cash
- CN¥36.6M cash at year-end CN¥36.7M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PASW operating cash flow, capex and free cash flow
PASW cash flow trends, FY2021–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −CN¥31.4MFY2021 | −CN¥6.4MFY2025 | — | |
| Capital expenditures | CN¥26,991FY2021 | CN¥0FY2025 | −100.0% | |
| Free cash flow | −CN¥31.4MFY2021 | −CN¥6.4MFY2025 | — | |
| Free cash flow margin | −31.6%FY2021 | −18.8%FY2025 | +12.7 pts | |
| Operating cash flow / net income | −6.02FY2021 | 2.92FY2022 | +8.94 | |
| Dividends paid | CN¥0FY2021 | CN¥0FY2025 | — | |
| Capex / revenue | 0.0%FY2021 | 0.0%FY2025 | 0.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PASW cash flow by activity
PASW net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PASW cash flow statement in Chinese yuan
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −CN¥12.8M | −CN¥1.3M | −CN¥993,937 | CN¥7.2M | CN¥5.2M |
| Depreciation & amortization | CN¥5,585 | CN¥10,239 | CN¥32,756 | CN¥24,651 | CN¥391,493 |
| Change in working capital | −CN¥1.4M | CN¥15.8M | −CN¥5.1M | CN¥14.0M | −CN¥38.7M |
| Other non-cash items | CN¥7.8M | CN¥138,403 | CN¥22,378 | −CN¥144,044 | CN¥1.7M |
| Cash from operating activities | −CN¥6.4M | CN¥14.6M | −CN¥6.1M | CN¥21.1M | −CN¥31.4M |
| Investing activities | |||||
| Capital expenditures | CN¥0 | CN¥0 | CN¥0 | −CN¥24,779 | −CN¥26,991 |
| Investments (net) | — | CN¥15.0M | −CN¥3.4M | −CN¥30.3M | −CN¥26,991 |
| Acquisitions & other investing | — | CN¥0 | CN¥0 | CN¥24,779 | CN¥26,991 |
| Cash from investing activities | — | CN¥15.0M | −CN¥3.4M | −CN¥30.3M | −CN¥26,991 |
| Financing activities | |||||
| Dividends paid | CN¥0 | −CN¥322,412 | −CN¥9.6M | −CN¥4.8M | CN¥0 |
| Net borrowing (repayment) | −CN¥33.5M | −CN¥29.8M | CN¥18.5M | CN¥15.1M | CN¥6.1M |
| Shares issued | CN¥108.2M | CN¥0 | CN¥0 | CN¥7,272 | CN¥0 |
| Other financing | −CN¥31.1M | CN¥0 | CN¥0 | CN¥0 | CN¥25.3M |
| Cash from financing activities | CN¥43.7M | −CN¥30.1M | CN¥8.9M | CN¥10.2M | CN¥31.4M |
| Summary | |||||
| Net change in cash | CN¥36.6M | −CN¥460,951 | −CN¥574,664 | CN¥1.1M | −CN¥53,014 |
| Cash at end of period | CN¥36.7M | CN¥130,923 | CN¥591,874 | CN¥1.2M | CN¥105,710 |
| Free cash flow | −CN¥6.4M | CN¥14.6M | −CN¥6.1M | CN¥21.1M | −CN¥31.4M |
| Free cash flow margin | −18.8% | 16.7% | −7.4% | 18.4% | −31.6% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating cash flow / net income | — | — | — | 2.92 | −6.02 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Chinese yuan as reported; data from EODHD.
PASW cash generation
In fiscal 2025 (ended September 30, 2025), Ping An Biomedical generated -CN¥6.4 million of cash from operations (down 143.9%) and spent CN¥0 on capital expenditures, leaving free cash flow of -CN¥6.4 million, −18.8% of revenue. Cash and equivalents rose by CN¥36.6 million over the year.
Related: PASW income statement, PASW balance sheet. See the PASW stock overview for the latest quote and news.
PASW cash flow FAQ
What is Ping An Biomedical's free cash flow?
Ping An Biomedical's free cash flow was -CN¥6.4 million in fiscal 2025: -CN¥6.4 million of operating cash flow minus CN¥0 of capital expenditures It was CN¥14.6 million a year earlier..
How much cash does Ping An Biomedical generate from operations?
Ping An Biomedical generated -CN¥6.4 million of cash from operating activities in fiscal 2025.